Abbott ABT announced
today it has received 510(k) clearance from the U.S. Food and Drug
Administration for a new in vitro diagnostic test to aid in determining the
prognosis of patients with acute myeloid leukemia (AML), one of the most
common types of leukemia in older adults.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in